Midwestern Medical Center Signs New Contract for Streamline Health® eValuator™

Automated Coding Analysis for Inpatient and Outpatient Care

ATLANTA, April 07, 2021 (GLOBE NEWSWIRE) —
Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of the eValuator™ Revenue Integrity Program to help healthcare providers proactively address revenue leakage and compliance exposure, today announced it has signed a contract with a 287-bed, Meditech EMR-based health system in Northern Ohio. As an opportunity created by Streamline’s network of channel partners, this regional provider will use eValuator’s cloud-based automated pre- and post-bill coding analysis technology to help improve revenue integrity for their inpatient and outpatient services.

Streamline Health is leading an industry movement to enable every hospital in the country to use pre-bill technology to improve financial performance. With eValuator, providers are identifying and addressing coding issues before they contribute to revenue leakage, denied claims and non-compliance exposure. The company combines this new technology with expert auditing services to deliver a complete Revenue Integrity Program to its clients. The eValuator program helps users optimize coding and documentation accuracy for every patient encounter prior to billing, substantially improving current financial performance while also assisting in the transition to new payment models.

“It’s very encouraging to partner with yet another Midwestern organization and to add to our roster of Meditech-based customers,” stated Tee Green, President and Chief Executive Officer, Streamline Health. “Providers of all sizes are equally committed to ensuring revenue integrity and improving their financial performance, and we’re honored to help them achieve both goals.”


About Streamline Health

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a leader in pre-bill revenue integrity solutions for healthcare providers. Our eValuator™ Revenue Integrity Program includes integrated solutions, technology-enabled services and analytics that drive compliant revenue and improved financial performance across the enterprise. We share a common calling and commitment to advance the quality of life and the quality of healthcare – for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.


To Learn More


Randy Salisbury
Senior Vice President, Sales & Marketing
Streamline Health
404.229.4242
[email protected] 



Mydecine Announces API-naming structure of Four Lead Candidates and Prepares for Pre-IND

DENVER, April 07, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced its four lead novel drug candidates as the Company prepares for its Pre-Investigational New Drug (IND) meetings with the FDA and Health Canada.

“Our first four novel drug candidates deliver on our long-term strategic road map for drug development with regular milestones that iteratively add value over time. By increasing the complexity of these compounds, we are increasing layers of patents applied, which in turn, also adds pharmaceutical value to the drug candidates,” said Joshua Bartch, Co-Founder and CEO, Mydecine Innovations Group. “The promise of these molecules is undeniable. By providing scalable, more stable compounds and delivery mechanisms for research and development, it means that new treatments for previously untreatable mental illnesses are close at hand.”

The four initial drug candidates include:

  • MYCO – 001 is pure psilocybin from natural fungal sources. Its target uses include mid-to-late stage clinical trials.
  • MYCO – 002 is an entactogenic compound that has been created with the goal of reducing harm and improving the safety profile vs. traditional MDMA.
  • MYCO – 003 is a psilocybin-based formula with reduced anxiety potential, with the aim of removing the possibility of “bad trips,” even with severely ill patients.
  • MYCO – 004 is a patch delivered tryptamine compound. Properties include short duration (~2hours), transdermal, precision dosing and long-term compound stability. The target use is mid-to-late-stage clinical trials, taking advantage of current publicly-available data.

These drug candidates were developed with the research team at Mydecine, led by Chief Science Officer and Co-Founder of Mydecine, Rob Roscow, along with collaboration from Dr. Denton Hoyer, drug-discovery expert and Mydecine Scientific Advisory Board Member. Mydecine believes that these drug candidates are unique and patentable in the United States and Canada and has received advice from counsel confirming such belief.

“In addition to Mydecine’s natural product portfolio, we believe these natural compounds also provide excellent starting points for new compounds which further meet the demands of the clinic and have improved safety, efficacy and formulation properties. Our research focus on molecular design achieves these goals,” said Dr. Hoyer.

“These candidates add layers of safety and dose-ability for the use of psychedelic compounds in medical research and eventually medical practice,” said Mr. Roscow. “We are essentially taking the value that is currently present in natural molecules, such as the psilocybin molecule in MYCO-001, and adding in patentable safety features. We want to create attractive features for the research community by providing compounds that can enhance therapy, reduce anxiety, and maximize delivery mechanisms.”

About Mydecine Innovations Group

Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

For more information, please contact:

Media Contacts

Anne Donohoe / Nick Opich
KCSA Strategic Communications
[email protected]
1-212-896-1265 / 1-212-896-1206

Investor Contacts

Charles Lee, Investor Relations
[email protected]
1-720-277-9879

Allison Soss / Erika Kay
KCSA Strategic Communications
[email protected]
1-212-896-1267

On behalf of the Board of Directors:

Joshua Bartch, Chief Executive Officer [email protected]

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at


www.mydecine.com


.

This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.



Mednow Engages Independent Trading Group for Market Making Services

Mednow Engages Independent Trading Group for Market Making Services

VANCOUVER, British Columbia–(BUSINESS WIRE)–
Mednow Inc. (TSXV: MNOW) (“Mednow” or the “Company”), Canada’s on-demand virtual pharmacy, is pleased to announce that it has entered into an agreement with Independent Trading Group (“ITG”), an arm’s length party to the Company, to provide market making services for a period of 3-months with the objective of maintaining a reasonable market and improving the liquidity of its securities.

Under terms of the agreement, the Company has agreed to pay ITG a fee of $6,500 per month, plus applicable taxes. ITG will not be subject to any performance factors or receive any securities of the Company as compensation. ITG does not currently own any securities of the Company; however, ITG may acquire a direct interest in the securities of the Company. The capital used for market making will be provided by ITG and will be done in accordance with TSXV policies and securities laws. The agreement is subject to acceptance for filing by the TSX Venture Exchange.

About Mednow Inc.

Mednow is a healthcare technology company offering virtual access with exceptional care. Designed with access and quality care in mind, Mednow.ca provides virtual care with convenience and through an interdisciplinary approach to healthcare that is focused on the patient experience. Pharmacy services include free at-home delivery of medications, a user-friendly interface for easy upload, transfer and refill of prescriptions, access to healthcare professionals through an intuitive chat experience, a specialized PillSmart™ system that packages prescriptions and vitamins by date and time, as well as access to telemedicine virtual care.

To learn more, follow Mednow on Facebook, Twitter, LinkedIn and Instagram, as well as visit www.mednow.ca/

On Behalf of the Board of Directors,

Karim Nassar

Karim Nassar

Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investor Relations Contact:

Marc Charbin

[email protected]

1.855.686.6300

Media Contact:

Jalila Singerff

Jive PR + Digital

www.jiveprdigital.com

[email protected]

613.614.6777

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Health Technology Other Health Mobile/Wireless General Health Pharmaceutical Internet

MEDIA:

Logo
Logo

Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 15 at 12 p.m. ET. The fireside chat will be moderated by Arlinda Lee, Ph.D., Managing Director, Biotechnology Analyst at Canaccord Genuity.

A live webcast of the event will be accessible in the Investors & Media section of Olema’s website. A replay of the webcast will be available.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Investor Contact:
[email protected]

Media Contact:
Sheryl Seapy, Real Chemistry
[email protected]
949-903-4750



Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

DURHAM, N.C.–(BUSINESS WIRE)–
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 12:45 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.

The fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of each fireside discussion will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

Media: Tad Heitmann 949-526-8747; [email protected]

Investors: Ami Bavishi 908-947-3949; [email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: FDA Health Clinical Trials Pharmaceutical Optical Biotechnology

MEDIA:

Logo
Logo

Conformis, Inc. to Release First Quarter 2021 Financial Results on May 5, 2021

BILLERICA, Mass., April 07, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time.

Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call also on Wednesday, May 5, 2021, at 4:30 p.m. Eastern Time to discuss the financial results and to provide a business update.

The webcast will be live at: https://edge.media-server.com/mmc/p/vnzdh2h9.

To attend by telephone, please use the information below for dial-in access.  

  • When prompted on dial-in, please utilize conference ID: 8727027.
  • Participant conference numbers (877) 809-6331 (U.S./Canada) and (615) 247-0224 (International).
  • Please dial in at least 10 minutes before the call to ensure timely participation.

Please visit the Investor Relations website at ir.conformis.com on May 5, 2021 to view the earnings release prior to the webcast and conference call.

The online archive of the webcast will be available on the company’s website at ir.conformis.com for 30 days.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.



Contact

Investor Contact:
Investor Relations
[email protected]
(781) 374-5598

Aramark Announces Upsized Revolving Credit Facility and Closing of Debt Refinancing

Aramark Announces Upsized Revolving Credit Facility and Closing of Debt Refinancing

Upsized Revolver increases cash availability by over $200 million

Proactive actions extend maturities and strengthen financial flexibility

PHILADELPHIA–(BUSINESS WIRE)–
Aramark (NYSE:ARMK), a global leader in food, facilities management and uniforms, announced today that the Company finalized a 3-year extension on substantially all of its Revolving Credit Facility and Term Loan A to 2026. This action included an upsizing of Aramark’s Revolving Credit Facility to approximately $1.2 billion that increases the Company’s cash availability by over $200 million. In addition, Aramark closed its previously announced $833 million refinancing of the Company’s 2024 Term Loan B that extends the maturity to 2028.

The transactions are net leverage neutral, while maintaining comparable fixed-to-floating debt levels.

“With a favorable outcome of the debt refinancing and upsized revolving credit facility, we have enhanced our financial flexibility and believe we are well-positioned to capitalize on the extensive growth opportunities ahead,” stated Tom Ondrof, Aramark’s Chief Financial Officer.

About Aramark

Aramark (NYSE: ARMK) proudly serves the world’s leading educational institutions, Fortune 500 companies, world champion sports teams, prominent healthcare providers, iconic destinations and cultural attractions, and numerous municipalities in 19 countries around the world. We deliver innovative experiences and services in food, facilities management and uniforms to millions of people every day. We strive to create a better world by making a positive impact on people and the planet, including commitments to engage our employees; empower healthy consumers; build local communities; source ethically, inclusively and responsibly; operate efficiently and reduce waste. Aramark is recognized as a Best Place to Work by the Human Rights Campaign (LGBTQ+), DiversityInc, Equal Employment Publications and the Disability Equality Index. Learn more at www.aramark.com or connect with us on Facebook and Twitter.

Forward-Looking Statements

Certain statements made in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are based on management’s expectations, estimates, projections, and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Additional information regarding these factors is contained in the “Risk Factors,” “Legal Proceedings” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections and other sections of Aramark’s Annual Report on Form 10-K, filed with the SEC on November 24, 2020, as such factors may be updated from time to time in its other periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and which may be obtained by contacting Aramark’s investor relations department via its website at www.aramark.com.

Inquiries

Felise Glantz Kissell (215) 409-7287

[email protected]

Scott Sullivan (215) 238-3953

[email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Food/Beverage Other Retail Retail Professional Services Other Professional Services

MEDIA:

Logo
Logo

Danaos Corporation Mourns the Passing of Former Board Member Robert Mundell

Danaos Corporation Mourns the Passing of Former Board Member Robert Mundell

ATHENS, Greece–(BUSINESS WIRE)–
Danaos Corporation (NYSE: DAC), one of the world’s largest independent owners of containerships, is saddened to report the passing of Robert A. Mundell, who served as an invaluable member of Danaos’ Board of Directors from 2006, when the company went public, through 2015.

From 1974 until his recent passing, Mr. Mundell was a professor in the economics department at Columbia University in New York, where he held Columbia’s highest academic rank of University Professor. For much of his career in academia, he was unconventional in his thinking and delighted in stepping “on a lot of intellectual toes.” Known as the “father of the Euro,” Mr. Mundell laid the groundwork for its introduction and also helped to start the movement known as supply-side economics. He received the Nobel Memorial Prize in Economics in 1999 for his pioneering work in monetary dynamics and optimum currency areas. The Nobel committee noted that Mr. Mundell “chose his problems with uncommon – almost prophetic – accuracy in terms of predicting the future development of international monetary arrangements and capital markets.”

Mr. Mundell is survived by his wife Valerie, his children Nicholas, Bill and Robyn and eight grandchildren. The members of Danaos’ management team mourn his passing and extend their most sincere condolences to his family.

About Danaos Corporation

Danaos Corporation is one of the largest independent owners of modern, large-size containerships. Our current fleet of 65 containerships aggregating 403,793 TEUs, including five vessels owned by Gemini Shipholdings Corporation, a joint venture, ranks Danaos among the largest containership charter owners in the world based on total TEU capacity. Our fleet is chartered to many of the world’s largest liner companies on fixed-rate charters. Our long track record of success is predicated on our efficient and rigorous operational standards and environmental controls. Danaos Corporation’s shares trade on the New York Stock Exchange under the symbol “DAC”.

Visit our website at www.danaos.com

Company:

Evangelos Chatzis

Chief Financial Officer

Danaos Corporation

Athens, Greece

Tel: +30 210 419 6480

E-Mail: [email protected]

Iraklis Prokopakis

Senior Vice President & Chief Operating Officer

Danaos Corporation

Athens, Greece

Tel. +30 210 419 6400

E-Mail: [email protected]

Investor Relations and Financial Media:

Rose & Company

New York

Tel. 212-359-2228

E-Mail:  [email protected]

 

KEYWORDS: Europe United States Greece North America New York

INDUSTRY KEYWORDS: Maritime Transport Logistics/Supply Chain Management

MEDIA:

The Movie Studio Inc. Announces the Release of ‘RETRIBUTION’ Moviesode 2

New locations have also been targeted for production of Moviesode 3

FORT LAUDERDALE, Fla., April 07, 2021 (GLOBE NEWSWIRE) — via InvestorWire – The Movie Studio, Inc. (OTC: MVES) (the “Company”) proudly announces the release of Moviesode 2 of the upcoming film “RETRIBUTION” (It’s Never Over), formerly titled “Cause & Effect.” View a trailer of RETRIBUTION Moviesode 2 at: https://vimeo.com/528989011.

RETRIBUTION Moviesode 2 stars Argentinian music artist Soleil. The talented Argentinian is taking the urban Latino market by storm. Soleil’s new song, “Voy, Voy, Voy” is featured in RETRIBUTION Moviesode 2. An aggregation of the music video in whole or in part is intended to be integrated into the completed feature film.

RETRIBUTION Moviesode 2 also stars Tito Puente Jr. who carries his father’s roots with him on screen as he delivers a powerful performance, cementing his presence in feature films. The movie also stars Karmel Bortoleti, a major talent coming from the modeling and print world, who showcases her crossover talent as a serious actress surely to be recognized in the industry as a new face and force in the motion picture industry.

Bortoleti was recently photographed for MAXIM by fashion photographer and director Messi Schneider, who sought to capture a simple, but sophisticated, concept on his recent Miami shoot. Schneider, who has shot top models Gisele BundchenCandice Swanepoel, Coco Rocha, Karolina Kurkova and Stella Maxwell, teamed up with local stylist Liandra Salles to curate looks that blend with the locale’s tropical vibe. Bortoleti shines in Faena Bazaar by Curio bikinis, a Louis Vuitton scarf, and Joie de Viv diamonds (https://www.maxim.com/style/karmel-bortoleti-by-messi-schneider).

The Movie Studio’s recently completed Moviesode 1 (https://vimeo.com/473177048/aaa0f80537) features the Company’s Moviesode process of fracturing linear production of motion picture manufacturing into chapters and, when assimilated, utilizes the core movie trailer (https://vimeo.com/397053717). Once complete, the feature film allows talent integration, location and product placement to add to the value proposition during the film’s fabrication process.

RETRIBUTION is the story of a Peruvian family that borrows money from “Mr. G” for their farm and when they fail to pay it back, Mr G sends in a “cleaner” who burns down their barn. When the father, mother and brothers rush in to save the horses, the roof collapses as a young    Natalia watches from the window as her family perishes.

Orphaned and abused by her new family, she emerges as an adult seeking “RETRIBUTION.” Natalia comes to Miami to find Mr. G and take care of “family business.” Going to work at Mr. G’s Dance Club, Natalia finds out she has been targeted for termination and thinks Mr. G has taken her out of the equation. But with the help of her sister, Natalia comes back for the final Venganza.

This fast, action thriller will keep you on the edge of your seat. Nothing is as it seems when it comes to “RETRIBUTION.”

The Movie Studio’s unique, disruptive process allows for content “bridges” into future Moviesodes for a potentially more structured completion of a motion picture, reducing the requirement for pickup shots using a traditional linear process, reducing the need for gearing up production, and reducing the capital expenditure associated with the traditionally linear process of motion picture manufacturing.

The Movie Studio has targeted two new locations in Fort Lauderdale, Florida, for filming of Moviesode 3 in April 2021.

The Company’s partnership with Vivalive.tv allows both companies to mutually benefit. Soleil’s talent addition to the Company’s Moviesode 2 surely shows the beneficial, vertical alignment of serious talent between the two companies.

“We are excited to release Moviesode 2 Retribution ‘It’s Never Over,’ formerly Cause & Effect, with great new artwork taking the feature film to the next level,” said Gordon Scott Venters, president and CEO of The Movie Studio. “We are utilizing our unique format of abbreviated motion picture content manufacturing as we move forward with our own streaming platform and app, incorporating non-linear scenes for final aggregation, allowing participants to be involved in the ongoing development of the story and our ‘Everyone’s a Star’ model. We are excited to begin planning of Moviesode 3 of this exciting story.”

About The Movie Studio

The Movie Studio, Inc. operates as a vertically integrated motion picture production and distribution company. It acquires, develops, produces and distributes independent motion picture content for worldwide consumption in theatrical, video on demand, foreign sales, and on various media devices. The Movie Studio, Inc. is disrupting traditional media content delivery systems with its digital business model of motion picture distribution and intends direct server access of its content with geo-fractured territories for worldwide distribution. The Company was formerly known as Destination Television, Inc. and changed its name to The Movie Studio, Inc. in November 2012. The Movie Studio, Inc. was founded in 1961 and is headquartered in Fort Lauderdale, Florida.

For information on The Movie Studio, please visit the Company’s website at www.themoviestudio.com.

Contact:

Gordon Scott Venters
President & Chief Executive Officer
2542 E. Sunrise Blvd. #2104 Ft. Lauderdale, Florida 33304
[email protected]
Telephone: 954-332-6600

This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results, specifically in the areas of future sales growth and profitability. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

Wire Service Contact

InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a12ed2b6-b1da-49d4-93bb-1de584f85307



GR Silver Mining Announces $8 Million Bought Deal Financing

Canada NewsWire

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

VANCOUVER, BC, April 7, 2021 /CNW/ – GR Silver Mining Ltd. (TSXV: GRSL) (FRANKFURT: GPE) (OTCQB: GRSLF) (“GR Silver Mining” or the “Company”) – announces that it has entered into an agreement with Beacon Securities Limited (the “LeadUnderwriter“), as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters (collectively, the “Underwriters“), pursuant to which the Underwriters have agreed to purchase, on a “bought deal” private placement basis, 13,600,000 units (“Units“) at a price of $0.59 per Unit (the “Issue Price“) for aggregate gross proceeds to the Company of $8,024,000 (the “Offering“).  Each Unit will consist of one common share in the capital of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant“).  Each Warrant will be exercisable to acquire one common share for a period of 24 months following closing of the Offering at an exercise price of $0.74 per share.

The Warrants may be accelerated by the Company, at its sole option, at any time after the closing date of the Offering provided that the volume-weighted average closing price of the common shares of the Company on the TSX Venture Exchange is greater than or equal to $1.30 for a period of 60 consecutive trading days, by giving notice to the holders thereof and, in such case, the Warrants will expire at 4:00pm (Toronto time) on the earlier of: (i) the 30th day after the date on which such notice is given by the Company in accordance with the terms of the Warrants, and (ii) the actual expiry date of the Warrants.

The Company has granted the Underwriters an option, exercisable by the Lead Underwriter on behalf of the Underwriters, to purchase up to an additional 2,040,000 Units, for additional gross proceeds of up to $1,203,600, exercisable in whole or in part at any time up to 48 hours prior to the closing date of the Offering.

The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes.

The Offering is expected to close on or about April 27, 2021 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.  All securities issued under the Offering will be subject to a hold period in Canada expiring four months and one day from the closing date of the Offering.

In connection with the Offering, the Underwriters will receive: (i) a cash commission of 7.0% of the gross proceeds of the Offering; and (ii) that number of non-transferable compensation options (the “Compensation Options“) as is equal to 7.0% of the aggregate number of Units sold under the Offering.  Each Compensation Option is exercisable into one common share of the Company at the Issue Price for a period of 24 months from the closing date of the Offering.


The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About GR Silver Mining Ltd.

GR Silver Mining Ltd. is a Mexico-focused company engaged in cost-effective silver-gold resource expansion on its key assets which lie on the eastern edge of the Rosario Mining District, Sinaloa, Mexico.

Plomosas Silver Project

GR Silver Mining owns 100% of the Plomosas Silver Project located near the historic mining village of La Rastra, within the Rosario Mining District. The Project is a past-producing asset where only one mine, the Plomosas silver-gold-lead-zinc underground mine, operated a 600 tpd crush milling flotation circuit from 1986 to 2001, producing approximately 8 million ounces of silver, 73 million pounds of lead and 28 million pounds of zinc.

The Project has an 8,515-hectare property position and is strategically located within 5 km of the Company’s San Marcial Silver Project in the southeast of Sinaloa State, Mexico.

The March 2020 acquisition of the Plomosas Silver Project included 563 historical and recent drill holes from both surface and underground locations. These drill holes represent an extensive database allowing the Company to advance towards resource estimation and potential project development in the near future.

The Company is carrying out a drilling program with surface holes focused on expanding known mineralization along strike in two initial areas, the Plomosas Mine Area and the San Juan Area. Underground drilling included in the program will target the extension of recent Au-rich discoveries at the lowest level (775 m RL, or ~250 m below surface) of the Plomosas Mine Area and six low sulphidation epithermal veins at the San Juan Area. Both areas will be the subject of NI 43-101 resource estimations following completion of this drill program.

The 100%-owned assets include all facilities and infrastructure including: access roads, surface rights agreement, water use permit, 8,000 m of underground workings, water access, 60 km – 33 KV power line, offices, shops, 120-person camp, infirmary, warehouses and assay lab representing approximately US$30 million of previous capital investments. The previous owners invested approximately US$18 million in exploration, including extensive geophysics and geochemistry programs.

The silver-gold mineralization on this Project displays the alteration, textures, mineralogy and deposit geometry characteristics of a low sulphidation epithermal silver-gold-base metal mineralized vein/breccia system. Previous exploration was focused on polymetallic (Pb-Zn-Ag-Au) shallow mineralization, hosted in NW-SE structures in the vicinity of the Plomosas mine. The E-W portion of the mineralization and extensions of the main N-S Plomosas Fault remain under-explored.

In addition to the resource potential at Plomosas, a review of the existing drill hole database, geophysical surveys and geochemical data covering most of the concession, has defined 16 new exploration targets from which 11 have high priority for future exploration programs.

San Marcial Project

San Marcial is a near-surface, high-grade silver-lead-zinc open pit-amenable project. The Company filed a National Instrument 43-101 (“NI 43-101”) report entitled “San Marcial Project Resource Estimation and Technical Report, Sinaloa, Mexico” having an effective date of March 18, 2019 and an amended date of June 10, 2020 (the “Report”), which contains a 36 Moz AgEq (Indicated) and 11 Moz AgEq (Inferred) resource estimate. The Report was prepared by Todd McCracken and Marcelo Filipov of WSP Canada Inc. and is available on SEDAR. The company recently completed over 320 m of underground development in the San Marcial Resource Area, from which underground drilling is planned to expand the high-grade portions of the resource down-dip. The Company recently discovered additional mineralization in the footwall, outside of the existing resource, and will also be drilling this area. GR Silver Mining is the first company to conduct exploration at San Marcial in over 10 years.

Recent exploration has identified silver and gold mineralization in areas previously defined as non-mineralized, discovering evidence of pervasively altered rocks with intense silicification, veining and associated wide, silver and gold mineralized zones on the footwall of the NI 43-101 resource area. Plomosas and San Marcial collectively represent a geological setting resembling the multi-millionounce San Dimas Mining District which has historically produced more than 600 Moz Ag and 11 Moz Au over a period of more than 100 years.

La Trinidad Project

The La Trinidad Project was acquired in March 2021. While La Trinidad has been the focus of artisanal mining activity over many decades, commercial operations began late in the 20th century. Anaconda Minerals Corp. was first to drill the project in the mid-late 1980s. After initially taking up an option on the Project in 1993, Eldorado Gold Corp. then commenced an open pit gold mine at La Trinidad in 1995, known as the Taunus Pit, with ore being processed via a heap leach operation. The mine operated until 1998, producing approximately 52,000 ounces of gold1.

Exploration undertaken by Oro Gold from 2006 identified additional resources below the Taunus Pit and operations recommenced late in 2014. Gold output from the heap leach pads continued until late 2019 for a total cumulative production by Oro Gold of 112,000 oz gold 2,3. In addition to La Trinidad, the portfolio acquired by GR Silver Mining includes an extensive regional database of geological, geochemical and geophysical information resulting from historical exploration expenditure by Oro Gold of more than CDN$18.6 million since 2006.

Cimarron Project

Cimarron is another advanced stage project that was acquired along with the La Trinidad Project in March 2021 and is located 40 km to the NW of La Trinidad. A number of targets have been identified at Cimarron including Calerita, El Prado, Huanacaxtle, Betty and Veteranos, however Calerita is the only target to have been drilled to date. The near surface historical Inferred Resource at the Calerita prospect contains 3.7 Mt at 0.65 g/t Au for approximately 77,000 oz of gold4, which is considered to be open along strike and down dip.

Whilst the 2011 resource is considered by GR Silver Mining to be a historical resource, the Company considers the resource estimate as being relevant and reliable, considering a lack of significant additional exploration work since its release. A key parameter in the historical resource is the usage of a US$1,200/oz gold price compared to a much higher current spot gold price. A Qualified Person (QP) would be required to review the historical resource report and make recommendations in order to verify and upgrade it to a current resource. A QP has not done sufficient work to classify the historical estimate as current mineral resources. The Company is not treating the historical estimate as a current mineral resource. The company plans to re-assess the work completed by previous owners and define the feasibility of additional drilling, aiming at identifying additional near-surface mineralization.

Other Projects

GR Silver Mining’s other projects are situated in areas attractive for future discoveries and development in the same vicinity of Plomosas, La Trinidad and San Marcial in the Rosario Mining District. Following the acquisition of Marlin, GR Silver Mining controls a concession portfolio of over 1,000 km2, two previously producing mines fully permitted for future developments and a total combined 75 km of structures with field evidence of 24 Ag-Au veins in historic old workings.

Mr. Marcio Fonseca
P. Geo, President & CEO
GR Silver Mining Ltd.   

____________________


1 Refer to Marlin Gold Mining Ltd. (Marlin) NI 43-101 News Release dated February 1, 2013 


2 Refer to Marlin MD&A Releases dated 30 April 2015, 29 April 2016, 1 May 2017, 30 April 2018, 29 August 2018


3 Refer to Mako Mining Corp. MD&A Releases dated 28 August 2019, 29 April 2020 


4 Refer to Marlin NI 43-101 News Release dated March 18, 2011                                        

Facebook LinkedInTwitter

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this press
release.


Disclaimer for Forward-Looking Information

This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations. Forward-looking statements and forward-looking information include, but are not limited to, statements with respect to the timing and completion of the Offering, the use of proceeds of the Offering and the availability of regulatory approvals for the Offering. Except for statements of historical fact relating to the Company, certain information contained herein constitutes forward-looking statements. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Such statements and information reflect the current view of the Company. Risks and uncertainties may cause actual results to differ materially from those contemplated in those forward-looking statements and information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

SOURCE GR Silver Mining Ltd.